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                                                  Abstract 
 
TITLE OF THE ABSTRACT : Hyperuricemia in renal allograft recipients   
DEPARTMENT   : Department of Nephrology  
NAME OF THE CANDIDATE     : Dr. Suraj Kumar 
DEGREE AND SUBJECT : DM (Nephrology) 
NAME OF THE GUIDE  : Prof. V. Tamilarasi 
 
AIM / OBJECTIVES:  
The primary objective was to assess the prevalence, clinical and biochemical predictors of 
hyperuricemia in renal allograft recipients. The secondary objective was to find association of 
graft function with hyperuricemia. 
MATERIAL AND METHODS:  
We conducted a retrospective study on 283 renal allograft recipients with at least 6 month 
follow up.  The data was recorded for each month till 6months and at 12th and 18th month and 
thereafter annually. We determined eGFR and occurrence of hyperuricemia, dyslipidemia, 
NODAT, acute rejection episodes. Hyperuricemia was defined as >6mg/dl in women and 
>7mg/dl in men and subdivided into early and late onset (<1>year) and mild and moderate to 
severe (<8>mg/dl). The statistical analyses were performed using SPSS software and 
independent t-test and Fisher’s exact test or chi square test were performed depending on 
variables.  
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RESULTS:   
 
The prevalence of hyperuricemia was 26.8%. The mean time to onset of hyperuricemia was 
6mths. Majority of the patients had early hyperuricemia (<12 months). Early onset moderate to 
severe hyperuricemia was seen in 29.5%. The incidence of NODAT and Dyslipidemia was 22% 
and 42% respectively. The nadir eGFR(73.0±27.5ml/min vs. 81.9±30.9ml/min, p value 0.03) and 
estimated GFR at 1month (68.5±21.0ml/min vs. 74.5±20.6ml/min, p value 0.04) were lower in 
patients with hyperuricemia.The incidence of NODAT (12.7% vs. 50.7%, p value 0.00) and serum 
triglyceride levels were higher (150.2±67.5mg/dl vs. 131.9±39.5mg/dl, p value 0.037) in patients 
with hyperuricemia. The recipients who had early onset moderate to severe hyperuricemia 
were found to have a lower estimated GFR at 1year (65.2±18.8 vs. 78.2±19.4, p value 
0.014)where as early onset mild hyperuricemia had no association with GFR at any time 
interval. 
CONCLUSIONS: 
 
The prevalence of hyperuricemia was 26.8%. Hyperuricemia was associated with a higher BMI 
at transplant, lower graft function, presence of NODAT and higher triglyceride levels. There was 
no association with recipient gender, deceased donor allograft or acute rejection episodes.  
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                                                            REVIEW OF LITERATURE 
                                                              Introduction 
Hyperuricemia has been commonly associated with renal and cardiovascular diseases. In 
patients with gout, before the availability of antihyperuricemic treatment, 25% of patients 
developed proteinuria, 50% had chronic kidney disease, and 10–25% had end stage kidney 
disease.1  
It is also more commonly seen in individuals with hypertension, obesity, metabolic syndrome 
etc. Over the years with widespread changes in dietary habits, there has been a worldwide 
epidemic of hyperuricemia, metabolic syndrome, obesity and type- 2-diabetes. 2 The animal 
models and experimental studies have further strengthened this association.  
But large epidemiological studies have not been able to prove this association (Framinghan 
study).3 The Modification of Diet in Renal Disease (MDRD) study also reported uric acid as a 
marker, rather than a predictor of renal function decline.4 The JNC 7 recommendations as well 
as the KDOQI guidelines also do not recognize it as a risk factor.  
There are also studies which support hyperuricemia as a primary risk factor for renal disease. In 
a study on Japanese population of 49000 males they showed that uric acid was one of the risk 
factors of renal failure with a relative risk (RR) of 8.52.5 Hyperuricemia also have been shown as 
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a risk factor for hypertension, decline in renal function, and tubulointerstitial changes in IgA 
nephropathy.6 
 
As the risk factors are so common in renal transplant setting hence it is even more common in 
the renal allograft recipients. The evidence for association of hyperuricemia with graft 
outcomes in renal allograft recipients is even more limited. In the precyclosporine era the 
prevalence of hyperuricemia was 25%. The use of cyclosporine led to a significant rise in the 
prevalence of hyperuricemia up to 80-85%. 7,8  Hyperuricemia also had a significant clinical 
impact with almost 10% patients developing gout.  
Over the years the type of immunosuppression has changed from predominantly cyclosporine 
to low dose tacrolimus now which has also reflected in a change in the prevalence of 
hyperuricemia. The results from ELITE-Symphony trial have shown a prevalence of 19-55%.9 ,10 
The lowest prevalence of hyperuricemia was seen in patients on low dose tacrolimus which was 
approximately 20%. In other solid organ transplant recipients also hyperuricemia is very 
common (14%-50% in liver transplant recipients). 11,12 
The common predictors of hyperuricemia are same as general population like metabolic 
syndrome, dyslipidemia, obesity, hypertension, use of diuretics as well as the factors specific 
renal transplant setting like NODAT, CsA use, graft function, chronic allograft nephropathy. As 
most of the studies have been cross-sectional in nature hence the causality remains unproven.  
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Only a limited number of studies have evaluated the effect of hyperuricemia on graft survival 
and dysfunction in renal allograft recipients and the results obtained have been quite 
contradictory. Also it is difficult to separate this association of uric acid with graft function. The 
hyperuricemia may simply be a consequence of the reduced graft function, as well as it can 
directly contribute to graft dysfunction. 
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Hyperuricemia has frequently been associated with various disorders like chronic kidney 
disease, cardiovascular diseases. It has also been associated with hypertension, obesity, 
metabolic syndrome. The experimental evidence is indeed there but the causality has not been 
conclusively established. The role of hyperuricemia in renal transplant setting is even more 
controversial and the evidence has been very inconsistent. 
 
 Uric acid metabolism 
Uric acid is the catabolic end-product of purines exclusively, which is metabolized by uricase 
enzyme to allantoin in majority of the mammals, except for humans and apes like chimpanzees 
and gorillas where this enzyme is absent. The beneficial effect of this is the proposed free 
radical scavenging effect of uric acid. But the downside of the absence of this enzyme is the 
much higher level of uric acid seen in us compared to other mammals which has led to gout and 
other complications. 
Biochemical pathway of uric acid synthesis in humans: 
The primary enzyme of this pathway is xanthine oxiadse  
1. It catalyzes the conversion of hypoxanthine to xanthine & then xanthine to uric 
acid. 
2. In humans this enzyme is present in liver and mucosa of small intestine 
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 Renal handling of Uric Acid and pathogenesis of Hyperuricemia 
Uric acid is freely filtered at the glomerulus, which is followed by reabsorption of almost 99% in 
proximal tubule, followed by 50% being secreted in S2 segment and 40% reabsorbed in S3 
segment. Hence it is almost completely reabsorbed in proximal tubules and only 10-15% is 
secreted in the tubules distally which amounts to 300-500mg per day.  
Hence uric acid is primarily handled by the kidneys and a significant proportion is reabsorbed 
leading to a fractional excretion of only 10%. 
 
Mechanism of uric acid transport in the kidneys: 
 The full mechanism is not elucidated but proximal tubule is the predominant site of urate 
secretion as well as re-absorption. The urate transport is bidirectional proceeding in a secretory 
as well as re-absorptive direction in proximal tubule. There are several urate transporters in the 
proximal tubule involved in this process. URAT1 is the most important anion exchanger involved 
in the re-absorption. It is expressed on the apical membrane of the proximal tubules. Similarly 
Glut9a, present on basolateral side plays an important role in uric acid reabsorption. 
BothURAT1 and Glut9a transport urate in exchange of multiple monovalent anions like chloride, 
lactate, or PZA in an electroneutral manner. The transporter proteins involved in urate 
secretion include ABCG2, MRP4, NPT1, and NPT4 located on luminal side of tubular cells, and 
OAT1 on the basolateral side.  
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An important factor determining the renal excretion of uric acid is contraction in 
extracellular fluid volume, leading to increased proximal urate re-absorption. This frequently is  
 
a case with use of diuretics. The lowering of fractional excretion of urate, along with an increase 
in sodium reabsorption, has also been observed in hypertension and in hyperinsulinemia.  
 
 
 
Table  1. Causes of hyperuricemia 
 
Primary hyperuricemia 
               Overproduction Idiopathic 
 
Glucose-6-phosphatase deficiency 
(Von Gierke’s disease) 
 
HGPRT deficiency (Lesch-Nyhan 
syndrome) 
 
 
Decreased excretion: 
 
Idiopathic 
 
Secondary hyperuricaemia 
 
 
        Excess production: 
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Increased turnover of nucleic acid Myeloproliferative disorder 
 
         Lymphoma, leukemia 
 
Multiple myeloma 
 
Cytotoxic therapy for 
malignancies 
 
Psoriasis 
 
Reduced ATP metabolism Alcohol  
 
Tissue ischemia 
 
       Reduced excretion: 
 
Decreased glomerular filtration - Renal failure 
 
Decreased secretion (due to competition 
for tubular secretion) 
- Lactic acidosis – alcohol, 
exercise  
 
Ketoacidosis  due to alcohol, 
diabetes, starvation 
- Drugs – low dose salicylate  
 
Increased reabsorption Hypovolemia, eg diuretics 
 
 Factors associated with hyperuricemia 
Renal dysfunction is an important factor causing hyperuricemia, where the decline in GFR 
decreases the total filtered amount of uric acid. The organic acids like lactate, β-
hydroxybutyrate and acetoacetate, which inhibit secretion of urate also cause hyperuricemia. 
Another important proposed cause of hyperuricemia is high fructose intake which has also 
been associated with the epidemic of obesity and metabolic syndrome. 
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 Potential pathophysiologic mechanisms in hyperuricemia 
There are two ways to explain the renal injury and other poor cardiovascular outcomes 
associated with hyperuricemia. Hyperuricemia can be an innocent bystander with other factors 
being responsible, which occur commonly with it, e.g. type 2diabetes, insulin resistance and 
metabolic syndrome. Epidemiological studies have shown that hyperuricemia is more 
commonly seen in individuals with hypertension, metabolic syndrome, diabetes, stroke, 
cardiovascular events. It can directly also lead to renal injury and various studies have shown 
that hyperuricemia is an independent risk factor for initiation of renal disease in individuals 
with normal renal functions as well as in progression of renal impairment in patients with 
CKD.13,14,15,16 
 
Role of Fructose intake in hyperuricemia and its association with metabolic syndrome.  
In the recent years prevalence of hyperuricemia has shown a rise which is parallel to the rise in 
obesity and metabolic syndrome. An analysis of the NHANES data showed a prevalence of 
hyperuricemia of 21.2% and 21.6% in men and women respectively. The study also showed a 
similar and related rise over the last 2 decades of obesity. 2,17,18 
The important link which has been proposed between hyperuricemia and obesity is high 
fructose intake. Fructose is a monosaccharide present in honey and various fruits. It also 
amounts to 50% of table sugar which is a disaccharide composed of two monosaccharides, 
glucose and a fructose. Fructose is also used in soft drinks, baked eatables, candies/sweets, 
jams and yogurts as a sweetener in form of high fructose corn syrup. Although overall sucrose 
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intake has declined, the intake of high fructose corn syrup in US has risen by almost 30% over  
the last 35 year which was also linked to a parallel rise in obesity, hyperuricemia and type 2 
diabetes .19,20,21,22 
The NHANHES third report supported this hypothesis that intake of sugar-sweetened beverages 
is associated with serum uric acid levels.23 Similar epidemiological studies have shown higher 
fructose consumption to be associated with gout and kidney stones.24 
 
Proposed mechanism of hyperuricemia, insulin resistance and metabolic syndrome in high 
fructose intake: 
Fructose is rapidly phosphorylated in hepatocytes to fructose-1phosphate with ATP acting as 
the phosphate donor. During this process the ADP which is generated is further changed into 
AMP depleting phosphate donors rapidly. This causes activation of enzyme AMP deaminase 
which in turn causes increase uric acid formation.  
Fructose-1-phosphate is further metabolized to glycerol-3-phosphate, which is important in the 
synthesis of triglycerides leading to its accumulation in skeletal muscle. The increase in 
intramyocyte triglyceride level is important factor in insulin resistance. This also explains the 
increase in metabolic syndrome and insulin resistance. Another factor is inhibition of carnitine 
palmitoyltransferase I, an important enzyme of fatty acid oxidation pathway in the myocytes. 
25The skeletal muscles are the most important site of insulin dependent glucose metabolism; 
hence it impairs a major mechanism of insulin dependent glucose metabolism. This has been 
verified in animal models and the elevation of intramyocyte triglyceride level is quite common 
in rats fed diet rich in uric acid.26,27,28 
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Figure  1. 
Pathway of uric acid synthesis from fructose 
 
                 
                                                                  
                                          ↓ 
                                
 
 
 
 
Baron et al proposed a novel hypothesis linking higher fructose intake, uric acid elevation, and 
insulin resistance.29  An important action of insulin is increase in blood flow to insulin sensitive 
tissues like skeletal muscle which promotes glucose utilization. This vasodilatory effect of 
insulin is mediated by endothelial nitric oxide synthase (eNOS).30 In obese individuals this 
insulin mediated vasodilation is impaired which contributes to insulin resistance. As uric acid is 
a potent inhibitor of eNOS, hence a hyperuricemic state found in obese individuals may be 
involved in the pathogenesis of insulin resistance in them. 
It’s almost over 100 years ago that Osler advised diets low in fructose for prevention of  gout. 
He wrote in 1893 that sugar to be reduced to a minimum and sweeter fruits not to be taken.31 
His astute observation indeed seems to be true in the light of the current knowledge. 
       Fructose -1Phosphate ADP 
       Fructose ATP 
      Fructokinase 
Uric acid 
AMP 
AMPdeaminase 
deaminasedeaminasedea
minase 
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Direct renal injury caused by hyperuricemia 
 The potential mechanisms behind it include inhibition of endothelial nitric oxide bioavailability, 
renin angiotensin system activation and direct actions on endothelial cells and vascular smooth 
muscle cells. 
 
Animal models of hyperuricemia  
In a rat model of hyperuricemia induced by feeding them oxonic acid (an inhibitor of uricase 
enzyme), Mazzali et al showed that hyperuricemic rats became hyperrtensive in 3 weeks, 
whereas control rats remained normotensive. They also noted that blood pressure could be 
reduced by treatment with either uricosuric agent (benziodarone) or a xanthine oxidase 
inhibitor (allopurinol) as well as oxonic acid withdrawal. The histological examination was 
normal by light microscopy whereas immunohistochemical stains showed ischemic damage 
with deposition of collagen and macrophage infiltration. These rats were also noted to have an 
increase in juxtaglomerular expression of renin with a reduction of neuronal NO synthase in 
macula densa and both the histopathological changes as well as hypertension were reduced 
with enalapril or L-arginine.32 
 In a similar study in rats made hyperuricemic by giving oxonic acid for 7weeks, the authors 
examined the renal biopsies. They compared hyperuricemic rats with control rats and there was 
a 30% increase in glomerular tuft area and it improved partially with use of enalapril.33 
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In a study by Kang et al in a 5/6 remnant kidney, the investigators examined the effect of 
hyperuricemia on renal disease progression, in rats fed oxonic acid for 6 wk with or without 
allopurinol or benziodarone.34 They studied the renal function and histology at 6 wk. They 
observed that hyperuricemic rats had higher BP, more proteinuria along with poor renal 
function. These rats had more renal hypertrophy and glomerulosclerosis with interstitial fibrosis. 
These rats also showed thickening of preglomerular arteries along with proliferation smooth 
muscle cell. There was also evidence that rats on allopurinol and benziodarone had significantly 
less changes. Also the expression of COX-2 and renin also was increased in the preglomerular 
arterial vessels.  
 
Proposed mechanisms of renal injury with hyperuricemia: 
 Effect on endothelial cell 
Hyperuricemia may cause endothelial dysfunction, which is supported by the evidence that 
lowering uric acid with allopurinol helps improving endothelial function, measured by brachial 
artery vasodilatation. 35  It has also been proposed as an inhibitor of NO production in 
endothelial cells by oxidants scavenging induced by NADPH oxidase under hyperuricemia36 and 
reduced bioavailability of NO. It also prevents endothelial repair by impairing endothelial cell 
proliferation.37  
Uric acid also acts as an antioxidant by scavenging hydroxyl free radicals, singlet oxygen species 
and peroxynitrite. It has been proposed to be acting as an antioxidant protecting us from aging 
consequences and malignancies.38 It has been shown to improve endothelial function in 
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diabetic patients after acute administration of uric acid39 and improves oxidant stress.40  But 
there have been contradictory views also where it has been shown to increase the oxidant 
stress.41 
 
 Effect on arteriolar disease and glomerular hemodynamic 
Hyperuricemia also alters glomerular hemodynamics.42 It caused cortical vasoconstriction in 
renal arterioles in a rat model. This led to a decline in glomerular plasma flow and ultrafiltration 
coefficient resulting in 35% decline in SNGFR along with rise in glomerular pressure and these 
changes were restored by allopurinol. 
 
Hyperuricemia also led to auto-regulation impairment in kidneys which led to an increase in 
transmission of increased systemic pressure to glomeruli causing  glomerular hypertension.42 It 
may be because of diseased afferent arteriole in hyperuricemic rats and allopurinol led to 
improvement in the same, improving renal autoregulatory response. Uric acid has also been 
shown to have an effect on plasma renin activity with amelioration of hypertension in 
hyperuricemia models with ACE inhibitors. 43, 34  
 
 
 
 
 
14 
 
 Hyperuricemia and hypertension 
 
Table  2. Susceptibility factors for renal disease in hypertension. 
 
 
 
 
 
 
 
Factors favouring increased risk for 
progression of renal disease in patients with 
essential 
hypertension 
Severe hypertension (systolic BP  170 mmHg) 
African Americans* 
Hyperuricemia  
Obesity / Metabolic syndrome* 
Use of diuretics * 
 
Decreased nephron endowment 
 
*Among these the African Americans, diuretic use, obesity and metabolic syndrome are 
associated with hyperuricemia 
 
 
Natural history studies before the era of effective of antihypertensive treatment noted that 35 
to 65% of patients with essential hypertension developed proteinuria, with one third patients 
developing renal insufficiency and 6 to 10% dying of end stage kidney disease. 1,44 
The classic pathological findings consisted of medial hypertrophy of interlobular and arcuate 
arteries later progressing into medial fibrosis with neointimal hyperplasia. Afferent arterioles 
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also showed thickening with hyalinosis, with subendothelial deposition of homogenous 
eosinophilic material. These findings suggested a significant injury into the vascular 
compartment of the kidneys. 45,46  
 
These findings put new light on the effect of various risk factors. Based on these data 
hypertension has been divided into 2 phases.47  
The initial phase is reversible whereas in the second phase the structural changes begin to start 
and then progress, leading to more and more kidney damage and other vascular changes. 
 
1. The first phase in hypertension is initiated primarily by extrarenal stimuli, which cause 
induction of renal vasoconstriction. These stimuli include hyperuricemia, angiotensin II, 
catecholamines, and dysfunction of endothelium impairing release of nitric oxide or drugs like 
cyclosporine. During this phase, the vascular structure in the kidneys are normal, but there is 
diffuse arteriolar vasoconstriction, leading to decline in renal plasma flow causing renal 
ischemia, tubular injury and interstitial inflammation 35,43 ,48,49 
 
2. In the second phase, there is renal cortical vasoconstriction that is irreversible despite 
removal of the original stimuli.50 It is associated with structural changes in the kidney which are 
arteriolosclerotic changes of the afferent arteriole along with interstitial inflammation. The 
importance of these changes have been delineated in animal models were both arteriolar and 
interstitial findings have been shown to have a key role in the hemodynamic response. The 
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inflammation (characterized by presence of monocyte/macrophages & T cells) plays a role by 
generating oxidants and angiotensin II, whereas structural changes in arteriole help in 
maintaining renal ischemia that incites this inflammatory reaction. 
The vasoconstriction is associated with decline in ultra filtration coefficient, cortical plasma flow 
and single-nephron GFR.43,51 But the GFR is decreased minimally because of the adaptation in 
juxtamedullary nephron.  
 
Animal models have indeed shown that hyperuricemia induces systemic hypertension and 
kidney injury by causing renal vasoconstriction mediated by endothelial dysfunction and renin-
angiotensin system activation. Over time, these models develop afferent arteriolar lesions, 
glomerular hypertension and hypertrophy, albuminuria, and finally glomerulosclerosis. 35, 43,52  
 
 
 Epidemiological evidence 
Garrod and Frederick described the relation of gout with uric acid and hypertension in early 19th 
century. In a cross-sectional study of patients with gout, Keenan et al observed multiple co 
morbidities in these patients. The majority of patients had features of metabolic syndrome, 
with 90% being hypertensive, more than 60% having hyperlipidemia and many suffering from 
chronic kidney disease, diabetes, and ischemic heart disease.53 There have been multiple 
epidemiological studies to determine whether uric acid is a risk factor for cardiovascular 
diseases with contradictory result.3,5 Hence most authors have concluded uric acid as just a 
17 
 
marker rather than a risk factor for cardiovascular disease. Both JNC 7 and KDOQI guidelines for 
chronic kidney disease have not included uric acid as a major risk factor. 
 
In recent studies role of uric acid in renal disease has been investigated in recent studies and 
has been supported as an independent risk factor for kidney disease in general population and 
for progression of renal diseases in those with established chronic renal disease and diabetes.54 
Also in a recent study in nontransplant population with an eGFR <60ml where the investigators 
randomized patients between allopurinol and conservative therapy found that allopurinol 
slowed renal progression.55 These findings do not conclusively prove that uric acid is a risk 
factor but it may help in improving the renal functions with kidney disease.  
Hyperuricemia has also been proposed as one of the components of metabolic syndrome56,57 
and as the prevalence of metabolic syndrome has increased, so is that of hyperuricemia. A 
recent study from United States using NHANES data showed a prevalence of hyperuricemia of 
21.2% and 21.6% in men and women respectively. It also showed that prevalence may have 
increased over the last 2 decades, which may be related to rising rates of obesity and 
hypertension. 2 
Hyperuricemia is rising even in developing countries. As the percapita income has increased 
and dietary habits are changing, the estimates from developing world also show a prevalence 
between 10-21%.7,8 
Hyperuricemia has been seen more commonly seen in individuals with hypertension, 
Dyslipidemia, obesity, metabolic syndrome, diabetes, alcoholism, renal dysfunction and who 
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are on drugs like diuretics, pyrazinamide etc. A significant number of these conditions are very 
commonly seen in renal transplant recipients. It makes quite logical that hyperuricemia would 
be seen very often in post transplant recipients.  The prevalence of hyperuricemia with 
cyclosporine based regimens was 80% which declined significantly with the current practice of 
low dose of tacrolimus.3 The data from Symphony trial shows the prevalence of hyperuricemia 
at 19-55%.4  
 Role of hyperuricemia in graft and patient survival 
 
Table  3. Role of immunosuppression in hyperuricemia  
Immunosuppression Serum Uric acid  
Cyclosporin A Increases  
Steroid Controversial 
Azathioprine No role (but requires dose modification if 
allopurinol is used) 
Mycophenolate No effect 
Sirolimus No role 
 
 
 Effect of immunosuppression on uric acid renal handling and metabolism 
1. CsA :  
a. Increased net tubular urate reabsorption58 
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b. Decreased glomerular filtration rate59 
c. Reduction in filtered load of uric acid.60 
 
 
2.  Steroid : 
a. Increased risk for insulin resistance and metabolic syndrome with well known 
association of metabolic syndrome and hyperuriccemia 
b. No direct effect on uric acid metabolism 
c. Controversial as effect confounded by other immunosuppressives. 
d. No studies of hyperuricemia from steroid free protocols 
3. Tacrolimus 
a. It has similar properties as cyclosporine 
b. The prevalence in tacrolimus-based regimens is less than that seen in studies 
with cyclosporine based regimens.61 
4. Azathiprine and Mycophenolate – No effect 
5. Sirolimus –  
a. No effect on uric acid renal handling and metabolism 
b. Studies with mTOR inhibitors based regimens in cyclosporine-free regimens had  
lower rates of hyperuricemia 
                         
 Evidence of hyperuricemia role in graft and patient survival 
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Hyperuricemia is common in post-renal transplant setting. The role of hyperuricemia in renal 
allograft outcome has been very contrdictory and is based mainly on small and retrospective 
studies. The results have been inconsistent and there are no randomized trials of lowering of 
hyperuricemia showing benefit in graft outcome. 
The hypothesis of all the studies have been based on the experimental evidence that 
hyperuricemia plays an important role in the pathogenesis of cardiovascular and renal disease 
by causing endothelial dysfunction by reducing nitric oxide and increasing smooth muscle 
proliferation. But whether uric acid is directly involved in the progression of renal worsening or 
it is just a marker of poor graft function is still an open question. The initial studies have mainly 
suggested it as a marker of poor graft function. 
 The data from the study by Gores et al in 1980 which analyzed patients on CsA with 
asymptomatic hyperuricemia showed no difference between hyperuricemic vs. 
normouricaemic patients in terms of graft outcome.62 They also showed a very low prevalence 
of gout in this cohort and suggested that asymptomatic hyperuricemia needs no treatment. In a 
recent study by Akgul et al in where they studied graft outcome at 3yr along with biopsy proven 
chronic allograft nephropathy and compared it with hyperuricemia at 3months.63 They found 
no relation between hyperuricemia at 3months with chronic allograft nephropathy and graft 
outcome at 3years but the prevalence of hyperuricemia increased over time. A recent study 
which analyzed the data from Symphony trial by Meier-Kriesche et al also showed a similar 
result.9 The authors studied 3-year follow-up data from Symphony trial and compared uric acid 
level at 1month with graft survival at 3 years. The predictor of elevated uric acid levels were 
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obesity, poor baseline graft function, initial randomization to Cyclosporin-A and deceased 
donor allograft. In a multivariate analysis they found that poor graft outcome at 3years, when 
adjusted for poor baseline graft function had no association with higher uric acid level.  
 
 Compared to these findings some studies have shown entirely contrasting results. In a study by 
Gerhardt et al., the investigators retrospectively analyzed the data of 350 kidney transplant 
patients. They found a significantly reduced graft survival in patients with elevated uric acid 
levels at 2, 4, and 5years post-transplant (92.2, 70.6, and 68.8% vs. 98.1, 85.6, and 83.3%) 
compared to recipients with normal uric acid levels. There was a significant association of uric 
acid levels with diuretic therapy and gender. They concluded that graft survival at 5yrs post-
transplantation was worse in hyperuricemic compared to normouricemic patients but they 
were unable to find any association of allopurinol therapy with graft outcome.64 Armstrong et al 
compared uric acid levels with estimated GFR at 2years and showed a significant association of 
uric acid levels with hypertension and graft function at 2years. 65  The investigators 
retrospectively analyzed data of 90 RTR with a median duration of follow-up of 7 years. The 
prevalence of hyperuricemia was 70% at baseline which increased to 80% after 2.2 years. UA 
levels were higher in patients who were taking ≥3 antihypertensive medications. The other 
predictors were prednisolone dose, estimated GFR and beta-blocker therapy. But the study had 
a very small sample size and a short period of follow-up. The investigators also measured the 
cyclosporine levels during this study.  There was no association between uric acid and drug 
levels. 
 
22 
 
Similarly in a retrospective study, Haririan et al evaluated the predictive value of mean uric 
acid in the initial 6 months after transplant for graft function and survival. They recruited 212 
live donor renal allograft recipients. The majority of patients were on tacrolimus and 
mycophenolate. The mean follow-up period was around 7years. They found that uric acid level 
and hyperuricemia were associated with graft loss independent of other variables. The risk of 
death also was more but did not achieve significance. The hyperuricemic patients were had a 
lower estimated GFR and graft loss also was 20% higher.66  
 
In another important retrospective study from Seoul by Min et al the authors analyzed the 
outcome of 281 renal transplant recipients. 67 They defined hyperuricaemia as early onset when 
it occurred within 1 year of transplant and late onset as after 1year and moderate to severe 
hyperuricemia as ≥8mg/dl. On multivariate analysis only early-onset moderate-to-severe 
hyperuricaemia was associated with chronic allograft nephropathy (P = 0.035) and poor graft 
survival (P = 0.026). The effect of moderate-to-severe hyperuricemia on graft survival was time 
dependent. The predictive value of moderate to severe hyperuricemia was seen even in 
recipients with preserved graft function (> 60 ml/min) at 1 year where it was found to be a 
marker of long-term graft dysfunction and failure. They also showed that early onset moderate 
to severe hyperuricemia was an independent risk factor for chronic allograft nephropathy. 
There was a dose response relationship with higher uric acid levels having poor graft function.  
Bandukwala et al in a retrospective study analyzed the association of hyperuricemia with 
inflammation, graft dysfunction, and cardiovascular events in 405 renal transplant recipients 
with stable renal function.68They included 405 stable renal allograft recipients who had ≥3 uric 
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acid and CRP measurement to determine the association of uric acid with CRP, rate of decline in 
the estimated glomerular filtration rate and cardiovascular events. They noted a prevalence of 
hyperuricemia of 44%. Hyperuricemia showed a negative association with estimated GFR and 
positive association with diuretic use, transplant vintage, and triglycerides. But the association 
of uric acid with CRP was rendered insignificant after adjustment for estimated GFR. The rate of 
decline in graft function was significantly higher in hyperuricemic recipients (p 0.003). Also 
there was a higher incidence of cardiovascular events in hyperuricemic recipients compared to 
recipients whose uric acid levels were normal (17 vs. 4, p = 0.001). Overall hyperuricemia was 
an independent predictor of lower eGFR and higher triglyceride level and higher cardiovascular 
morbidity. 
 
Recently in a meta-analysis by Huang et al in 2012 where they included twelve studies, they 
found that the renal transplant recipients with hyperuricemia had a lower estimated GFR (P, 
0.0001, 95%CI 6.34-6.14) and higher SCr (p 0.00001, 95%CI 0.17-0.31) compared to recipients 
with normal uric acid levels. The meta-analysis also noted that hyperuricemia was a risk factor 
of chronic allograft nephropathy (OR = 2.85, 95%CI 1.84-4.38) and loss of graft (OR = 2.29, 
95%CI 1.55-3.39).69 The results of this meta-analysis was important as it involved multiple 
studies which included patients from Asia, Mediterranean, Europe and North America making it 
representative of various  races. The second aspect was that the effect on renal function of uric 
acid levels was consistent even after adjusting for other confounding variables  
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Also to establish causality the other important evidence is improvement in graft function with 
uric acid lowering drug. There are no randomized trials but which have tested this hypothesis 
there are 2 nonrandomized trials which reported the effect of uric acid lowering therapy on 
renal allograft recipients. In a study by Flury et al published in 1977, the authors compared the 
effects of allopurinol vs. benzbromarone for uric acid lowering after kidney transplantation. 
They enrolled 17 renal allograft recipients with hyperuricemia who were treated with either 
allopurinol or benzbromarone. Both drugs reduced uric acid levels effectively. With allopurinol, 
the adverse reactions were increased azathioprine mediated bone marrow toxicity whereas in 
benzbromarone group no interactions were observed. The investigators did not observe any 
difference in the graft function. Hence they concluded that hypouricemic drugs were safe and 
effective but without an effect on graft function.70 A similar study by Navascues et al  showed 
that allopurinol use for uric acid lowering was safe in renal transplant recipients but similarly 
there was no difference in graft function71 as the serum creatinine did not show a significant 
change after treatment (2.35±0.92 mg/dl vs. 2.39±1.03 mg/dl). 
 
There was a recent small randomized controlled trial72 although in nontransplant patients 
where the investigators randomized 54 patients to allopurinol or the continuation of usual 
therapy for 1year. The serum creatinine level in the treatment arm was less but it did not reach 
a statistical significance (P = 0.08). Overall, After 12 months of treatment 16% in the treatment 
arm  reached the combined end points of >40% deterioration in renal function and dialysis 
dependence vs. 46.1% in the control group.  Although the limitation of this study was that it 
was a very small study. 
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Management of hyperuricemia in post renal allograft recipients  
 There are no recommendations, but mainly suggestions  
 
 KDIGO working group74 –  
1. To achieve weight loss 
2. To decrease meat and alcohol consumption 
3. To avoid diuretics 
4. Losartan is associated with 8% reduction in uric acid concentrations which is not a class 
effect. Can be substituted if any ARB/ACEi is indicated 
5. Asymptomatic hyperuricemia treatment is not advised 
6. Allopurinol is commonly used as a hypouricemic drug.  
7. If used together along with azathioprine can cause severe life threatening bone marrow 
suppression. It requires a 50% reduction of azathioprine dose  
 
 American Society of Transplantation73  
1. Measure uric acid every 2–3 months 
2. More frequent screening is needed in recipients with impaired graft function   and 
especially those who are on diuretics.  
 
 Caring for Australasians with Renal Impairment guidelines for patients with CKD 74 
1. Treatment of hyperuricemia does not reduce progression of kidney disease and is not 
recommended.  
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 European Best Practice guideline75 
1. The combination of allopurinol and azathioprine is to be avoided. 
 
Hence the conclusion can be drawn that there is enough experimental evidence for uric acid 
being a major risk factor for renal diseases but there is limited evidence from the trials, mainly 
from cross-sectional studies and there are even fewer randomized trials on benefit of treating 
hyperuricemia.  
So the jury is still out despite the experimental evidence, whether uric acid is just a 
marker of poor graft function or is it directly involved in the decline of graft function. 
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AIMS AND OBJECTIVES 
 
 
Primary objective 
 To assess the prevalence of hyperuricemia in renal allograft recipients.  
 To look for the clinical and biochemical predictors of hyperuricemia in renal allograft 
recipients.  
 
Secondary objective 
 To look for the association between graft function and hyperuricemia 
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MATERIALS AND METHODS 
 
 
STUDY DESIGN:  
• Retrospective observational study. 
 
SAMPLE SIZE:  
 Study was conducted on 284 consecutive recipients of renal allograft who underwent 
the transplant between 2008 July and 2011 June in the department of nephrology in 
Christian medical college, Vellore. 
 
INCLUSION CRITERIA 
 Consecutive patients who underwent renal transplant between 2007 january and 2011 June  
 
EXCLUSION CRITERIA  
Patients who did not have follow-up of at least 6months. 
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METHODS 
• Patients were studied till the last follow-up of June 2012 or till graft loss or death 
whichever was earliest.      
• Observation was recorded at each month till 6months post transplant and then at 12 
and 18th month. Thereafter it was recorded annually.   
 
• A detailed proforma was filled to document  
1. Demographics details including the age, height, weight and sex of the patient  
2. Clinical history including the native kidney disease along  
3. Biochemical parameters were also noted which included  
a. serum level of creatinine and lipid profile which is done monthly.  
4. Uric acid was recorded at the time of diagnosis of hyperuricemia. 
5. Treatment details especially the induction therapy, maintenance immunosuppression 
and antirejection therapy were noted. 
6. Presence of CMV disease and viremia also noted 
7. Estimated GFR was calculated at each visit using abbr. MDRD equation 
8. The donor details including the age, sex and weight were also included.  
     
  The data was collected from the transplant charts and hospital electronic data   base.  
 
 
30 
 
 
DEFINITIONS 
Hyperuricemia76 
Defined by working group of KDIGO taskforce for care of kidney transplant recipients as 
1. women  >0.36 mmol/L (6.0 mg/dL)  
2. men >0.42 mmol/L (7.0 mg/dL)  
 
Dyslipidemiia –  
ATPIII guideline77  
1. LDL cholesterol <100mg/dl 
2. Triglyceride < 150mg/dl 
3. HDL cholesterol (in men) < 40mg/dl 
4. HDL cholesterol (in women) <50mg/dl  
NODAT 
As defined by International consensus guidelines (published in 2003)78,79 
HbA1c (glycated hemoglobin) should not be used before 3 months after transplant 
Standard WHO and ADA criteria for diabetes mellitus diagnosis  
1. Symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) + random 
plasma glucose ≥200 mg/dL (11.1 mmol/L) 
2. Fasting (at least eight hours) plasma glucose ≥126 mg/dL (7.0 mmol/L) 
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3. 2 hour plasma glucose ≥200 mg/dL (11.1 mmol/L) upon oral glucose tolerance test 
( glucose load equivalent to 75 g anhydrous glucose in water) 
 Hypertension64  
  Defined by working group of KDIGO taskforce  for care of kidney transplant recipients as 
1. 140 mm Hg and/or diastolic blood pressure ≥90 mm Hg 
 
2. History of use of antihypertensives  
 
 
 
 Abbr. MDRD equation80 – 
4 parameter equation (demographic variables only) 
estimated GFR (ml/min/1.73m2) = 175*(serum creatinine in mg/dL)-1.154*[Age in years]-0.203 * 
[0.742 if patient is female] * [1.212 if patient an African American] 
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STATISTICAL METHODS 
 Statistical analyses were performed using SPSS software. 
 For continuous variables data was expressed as means ± standard deviations and for 
discrete variables as frequencies (percentages). 
 Means were compared using Student’s t-test, independent t-test for continuous variables.  
 Non-continuous variables were compared by using chi square and Fisher’s exact  Test. 
 Error bar plot was plotted for triglycerides, nadir eGFR and at eGFR 1month for showing the 
distribution of these variables in patients. 
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RESULTS 
 
We recruited 284 patients who underwent live related or deceased donor renal transplantation 
in our institution from June 2008 to June 2011 and who satisfied our inclusion and exclusion 
criteria. Baseline characteristics have been summarized in the following table. 
 
Table 4.  Demographic characteristics  
Demographic characteristics 
Recipient (Male:Female)  2:1 
Recipient Age (in years) (mean±SD)  36.7±11.97 
Donor (Male:Female) 1:2 
Donor Age (in years) (mean±SD) 41.08±11.6 
 
Demographic parameters  
Ours was relatively a younger cohort with a mean age of the patients being 36.7±12.0 years 
with a range of 7-63 years. Recipient group was skewed towards males with more number of 
males getting a renal transplant with male to female ratio of 2:1. Most of the donors were 
female with a male to female donor ratio of 1:2. The mean (±SD) donor age was 41.08±11.6 
years. 
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Baseline parameters  
Among the recipients diabetes was quite common with the prevalence of diabetes 
pretransplant being 34.5% (98recipients). Hypertension was also very common with 71.5% (203 
patients) being hypertensive pre-transplant. Majority of the patients were on hemodialysis 
prior to undergoing transplant (89.4%). Only 5patients were on peritoneal dialysis and 25 (8.8%) 
patients had a preemptive renal transplant. The mean duration of dialysis was 7.6months. 
 
Table  5. Baseline parameters 
Baseline parameters 
Live related donors % (n) 90.5%(256 ) 
Deceased donors % (n) 9.5%(28) 
Pre-transplant Hypertension % (n)  71.5%(203) 
Pre-transplant Diabetes % (n)  34.5%(98) 
BMI(Body Mass Index) kg/m2 20.8±3.4 
Preemptive renal transplantation% (n) 8.8%(25) 
Mean duration of dialysis (months) 7.6±8.06 
 
Native kidney disease: 
The underlying chronic kidney disease was unknown in the majority of the patients with 55.6% 
patients in this group. The other most important cause of chronic kidney disease was diabetic 
nephropathy. 20.4% patients had diabetic nephropathy. Patients with focal segmental 
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glomerulosclerosis and other chronic glomerulonephritis constituted 5.6% and 11.6% 
respectively. There were 5 patients in this cohort who had autosomal dominant polycystic 
kidney disease (1.8%). 5% patients had obstructive uropathy as the native kidney disease. 
 
. Figure  2.  Native kidney disease 
Diabetic nephropathy
Unknown
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Other chronic 
glomerulonephritis
ADPKD
Obstructive 
nephropathy
 
 
 Transplant details  
The majority of the patients received an allograft from a live related donor. Out of 284 
patients there were 256 (90.5%) live related renal transplantation and 28(9.5%) received a 
deceased donor kidney. 
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Immunosuppression  
Most of the patients received induction prior to the transplant. Out of 283 patients 246 
(86.9%) patients received induction. The most common induction regimen was Basiliximab 
(2 doses were given on day 0 and 4), which was given to 73.1% patients. 39(13.8%) patients 
received antithymoglobulin as induction agent whereas 37(13.1%) patients underwent 
transplant without induction. Post transplant 11patients (3.9%) had delayed graft function, 
requiring hemodialysis. Overall in the immediate post-transplant period, the nadir 
estimated GFR (mean±SD) was 79.2ml/min±30.2 and time period after which they achieved 
it was 9.2 ±9.4 days. 
 
Table  6. Induction Regimen 
 n(%) 
Basiliximab 207(73.1%) 
Antithymocyte globulin 39(13.8%) 
No induction 37(13.1%) 
 
Table 7.  Maintenance immunosuppression 
 n(%) 
Mycophenolate 267(94) 
Tacrolimus 258(90.8) 
Cyclosporin-A 15(5.3) 
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Azathioprine 11(3.9) 
 
The predominant immunosuppression used in our cohort was triple immunosuppression which 
included Mycophenolate, Tacrolimus and steroid. 94% patients were on mycophenolate and 
90.8% patients were on Tacrolimus. Cyclosporin-A was given to only 15 patients (5.3%) and 
Azathioprine to11 patients (3.9%). 
 
Table  8. Post transplant complications 
 n(%) 
Graft loss 9 
Death  11 
Dyslipidemia 120(42.1) 
NODAT 64(22.8%) 
 
Post transplant complications: 
The mean (±SD) duration of follow-up was 27.1±13 months. During the follow-up period 9 
patients had graft loss and 11 patients died, out of which 7 died with a functioning graft. There 
were 120 patients (42.1%) who had dyslipidemia post transplant period and 64 patients (22.8%) 
developed NODAT. Also 67(23.6%) patients had biopsy proven acute rejection. 
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Hyperuricemia 
Post transplant 85(26.8%) patients had hyperuricemia. The mean time to onset of 
hyperuricemia was 6mths. Majority of the patients had early onset hyperuricemia (<12 months) 
with only 11% patients having onset of hyperuricemia after 12months. The mean uric acid level 
in patients who had hyperuricemia was 7.8±0.96mg/dl. Among the patients who had 
hyperuricemia, around one third (29.5%) had moderate to severe hyperuricemia (>8mg/dl). We 
subdivided the hyperuricemic recipients on the basis of time of onset and severity. There were 
no differences in the baseline variables between early and late onset hyperuricemia  
 
Table 9. Distribution of baseline parameters between early and late onset hyperuricemia 
 Early onset 
hyperuricemia 
Late onset 
hyperuricemia 
p value 
Age (year) 36.9 34.0 0.44 
BMI (kg/m2) 21.2 22.0 0.60 
Durn of dialysis pre-
transplant (month) 
8.1 8.4 0.93 
Donor age 39.3 46.0 0.08 
Pre-transplant DM 37.9 36.4 0.8 
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Figure  3. Hyperuricemia Sub-classification 
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Association of hyperuricemia with baseline parameters 
The baseline demographic variables were similar among the hyperuricemic and normouricemic 
recipients. These included age (36.7±11.6 vs 36.6±12.2, p value 0.93), donor age (40.9±11.9 vs. 
41.1±11.5, p value 0.93), recipient sex and donor sex.  
 
The duration of dialysis prior to transplant was (7.5±0.9 months vs. 8.3±0.6 months, p value 
0.98) was also similar among the two groups. The number of patients who had pre-transplant 
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hypertension (78.3% vs. 78.1%, p value 0.9) or diabetes (38.7 vs. 32.2, p value 32.2) was also 
similar in both recipients with elevated uric acid levels and in those with normal levels. Among 
the baseline parameters only the BMI (body mass index) was significantly higher (21.8±4.7 vs. 
20.4±2.9, p value 0.98) in the hyperuricemic recipients. 
 
 Among the immunosuppressive drugs there was no significant difference in terms of treatment 
with mycophenolate, tacrolimus and azathioprine in hyperuricemic and normouricemic patients. 
But the proportion of patients using cyclosporine-A was significantly more common in 
hyperuricemic patients (10.7% and 3.4%, p value 0.031). 
 
Table  10.  Association of hyperuricemia with baseline parameters 
 
 Hyperuricemia Normouricemia p value 
Recipient Age(yr) 36.7±11.6 36.6±12.2 0.93 
Recipient BMI (kg/m2)         
(at transplant) 
21.8±4.7 20.4±2.9 0.024 
Donor Age (yr) 40.9±11.9 41.1±11.5 0.892 
Pre-transplant diabetes 38.7 32.2 0.321 
Pre-transplant 
hypertension (%) 
78.3 78.1 0.9 
Duration of dialysis 7.5±0.9 8.3±0.6 0.98 
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(months)pre-transplant 
 
Association of hyperuricemia with graft function  
The proportion of patients who had delayed graft function after transplant among 
hyperuricemic was higher compared to the normouricemic recipients but it did not achieve 
statistical significance (4.1% vs. 1.5%, p value 0.19). The hyperuricemic recipients had a 
significantly lower nadir estimated GFR (73.0±27.5ml/min vs. 81.9±30.9ml/min, p value 0.03) 
and estimated GFR at 1month (68.5±21.0ml/min vs. 74.5±20.6ml/min, p value 0.04). The 
estimated GFR at all other time intervals did not show any significant association with 
hyperuricemia. We also calculated the estimated GFR decline weighted for the time of follow-
up (nadir eGFR – eGFR at last visit /duration of follow-up in months).  This also was similar 
between the groups.  
 
During the follow-up period 9 patients lost their graft. The number of patients (6.8%) who lost 
their graft in the hyperuricemic group was higher compared to patients whose uric acid levels 
were normal (2%) but it was not statistically significant (p value 0.059). There was also no 
significant difference in terms of induction and acute rejection among the 2 groups.  
 
The incidence of NODAT was significantly higher in patients with hyperuricemia (50.7%, vs. 
12.7%, p value 0.00). The prevalence of dyslipidemia was higher but it did not achieve statistical 
significance (52% vs. 39.2%, p value 0.058). The level of serum triglyceride was higher in the 
patients with hyperuricemia (150.2±67.5mg/dl vs. 131.9±39.5mg/dl, p value 0.037). The levels 
of serum LDL cholesterol (93.9±25.3mg/dl vs. 96.0±31.0mg/dl, p value 0.583) and HDL 
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cholesterol (47.2±12.5mg/dl vs. 48.7±9.7mg/dl, p value 0.34) were similar. Also the incidence of 
CMV disease post transplant was similar in 2 groups. 
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Figure 4.  Error bar plot between hyperuricemia and nadir eGFR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Error bar plot between hyperuricemia and eGFR at 1mth 
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Figure   6.  Error bar plot between hyperuricemia and triglycerrides  
 
 
 
Table   11. Association of hyperuricemia with NODAT and dyslipidemia  
 
 Hyperuricemia Normouricemia  pvalue 
NODAT 50.7% 12.7% 0.00 
Dyslipidemia 52% 39.2% 0.058 
Serum 
 Triglyceride 
150.2±67.5mg 131.9±39.5 0.037 
Serum LDL 93.9±25.3 96.0±31.0 0.58 
Serum HDL 47.2±12.5 48.7±9.7 0.34 
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DISCUSSION 
  
We undertook a retrospective longitudinal study in the Department of nephrology, Christian 
medical college, Vellore to determine the factors influencing the occurrence of hyperuricemia 
in the patients undergoing renal transplantation in our department. We recruited 284 patients 
in the study who underwent either a live related or a deceased donor renal transplantation 
between the period of 2008, July to 2011 June. Our study population was skewed towards 
males. The male to female ratio in our cohort was approximately 2:1. Our study population 
mainly comprised of young adults to middle age group individuals with people in the group 
between 20-50 years comprising of almost 80% of the total recipients. The mean age of the 
recipients was 36.7±12.0 years. The mean BMI of our patient was 20.8kg/m2 with one fourth of 
the patients being underweight and with only 10% being overweight. Prior to transplant 71.5% 
patients had hypertension and 34.5% patients had diabetes. .Ours was predominantly a live 
related renal transplant recipient population (90.5%).  Among the live related renal recipients 
majority of the donors were females with the male to female ratio of 1:2. The mean donor age 
was 41.08±11.6 years. There was a gender bias, which is expected as other studies have also 
shown a similar trend. A retrospective study from PGI Chandigarh showed that among a cohort 
of 682 patients, 90% were males and among the donors 66% were females which is similar to 
our study.81 
 
The most common native kidney disease was of unknown etiology which constituted 55.6% of 
the population followed by diabetic nephropathy (20.4%). Other etiologies were obstructive 
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uropathy (5.0%), focal segmental glomerulosclerosis (5.6%), other chronic glomerulonephritis 
(11.6%) and ADPKD (1.8%). Only 9% patients underwent a preemptive renal transplantation, 
with majority being on dialysis with a mean duration of dialysis of 7.6months. Majority of the 
patients received an induction therapy prior to transplant with the maintenance 
immunosuppression being tacrolimus and mycophenolate based triple regimen. 
 
Post transplant the prevalence of dyslipidemia and NODAT were 42% and 22% respectively. 
Other studies also have shown a similar incidence of NODAT and dyslipidemia depending on the 
duration of follow-up and other risk factors. In a prospective study from Spain82 with a similar 
Tacrolimus based maintenance immunosuppression regimen, they showed an incidence of 
NODAT of 20% at 1year where as in another study where the investigators did an OGTT (oral 
glucose tolerance test) at 10 weeks found the incidence of NODAT to be 14%.83 Graft loss and 
death were uncommon event (9 and 11 respectively) but the mean duration of follow-up was 
less (27 months). Among the patients who died, 7 died with a functioning graft. 
 
Hyperuricemia 
 
The prevalence of hyperuricemia in our study was 26.8%. This is similar to studies which have 
been based on a similar maintenance immunosuppression. The ELITE – Symphony study also 
showed a similar prevalence of hyperuricemia ranging from 19-55%.There was no association 
between hyperuricemia and donor age, sex, deceased donor allograft, delayed graft function, 
pre-transplant diabetes or hypertension. Among the baseline variables only BMI at transplant 
had a significant association with hyperuricemia. We also could not find any association of 
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hyperuricemia with type of induction, maintenance immunosuppression and acute rejection 
except for the use of cyclosporine. But the number of patients on cyclosporine was very small. 
This was in contrast to the results of Min et al where they found that age and BMI at time of 
transplant, gender, history of hypertension and diabetes prior to transplant, deceased donor 
allograft, duration of dialysis were significantly associated with hyperuricemia. But other 
studies have shown similar results as our study. In a study by Akalin et al,84 the investigators 
could not find any association with recipient age, BMI and donor gender. The predictors of 
hyperuricemia in this study were male gender (63.9% and 49.7%, p0.012), deceased donor 
allograft (54.2% and 33.1%, p0.001), older donor age (41.8yr and 38.yr, p 0.014) and use of 
cyclosporine as maintenance immunosuppression. But similar to our study the incidence of 
acute rejection episodes was not higher in hyperuricemic recipients.   Hence the results have 
been contradictory. 
 
We also found that the incidence of NODAT was higher in patients with hyperuricemia 
compared to those whose uric acid levels were normal (12.7% vs. 50.7%, p value 0.00). 
Although dyslipidemia was not significantly associated with hyperuricemia but the mean level 
of serum triglyceride was higher in the patients with hyperuricemia (150.2±67.5mg/dl vs. 
131.9±39.5mg/dl, p value 0.037).  These results were similar to previous studies. The study by 
Akalin et al84 also showed a higher incidence of NODAT in patients with hyperuricemia (14.1% 
vs. 7.6%, p value 0.07) although it did not reach statistical significance. Similarly the study by 
Bandukwala et al68 found a significantly higher triglyceride levels in patients with elevated levels 
of uric acid (140±80mg/dl vs. 157±80, p value 0.02). As the diabetes, obesity, hyperuricemia are 
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all components of metabolic syndrome so it was expected. Although in the available literature 
there is a paucity of data on association of NODAT with hyperuricemia and also the risk factors 
of NODAT in transplant are different than in non-transplant setting.85,86  
In a recent study by Min et al67 they proposed that the early onset moderate to severe 
hyperuricemia is more strongly associated with graft dysfunction. So we also separately 
analyzed the data for patients with early onset moderate to severe hyperuricemia. Majority of 
patients had an early onset hyperuricemia (89%) which was similar to the study by Min et al67 
where the authors found that 3/4th of the patients had early onset hyperuricemia. The baseline 
variables in our study were similarly distributed between the early and late onset 
hyperuricemia groups.  
 
Association of hyperuricemia with graft function 
 The incidence of delayed graft function was statistically not different (4.1% vs. 1.9%, p value 
0.19). We also found that hyperuricemic patients had a lower nadir estimated GFR 
(73.0±27.5ml/min vs 81.9±30.9ml/min, p value 0.033) and estimated GFR at 1month 
(68.5±21.0ml/min vs 74.5±20.6ml/min, p value 0.034) post transplant compared to the patients 
with normal uric acid levels. But there was no difference in the graft function at subsequent 
time interval during the follow up. We also estimated the rate of decline in estimated GFR per 
month in recipients with hyperuricemia and that too was similar as in those with normal levels. 
This was similar to the study by Meier-Kriesche et al10 in which they showed that hyperuricemia 
correlated well with baseline estimated GFR but upon multivariate analysis there was no 
correlation with GFR at 3years. We also analyzed the association of early onset moderate to 
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severe hyperuricemia with graft function. The estimated GFR at 1 yr post-transplant was lower 
in patients with early onset moderate to severe hyperuricemia (65.2±18.8 vs. 78.2±19.4, p value 
0.014) although it did not have any association with nadir estimated GFR and GFR at 1 month 
post-transplant. We also analyzed the association of early onset mild hyperuricemia (<8mg/dl) 
with graft function and similar to Min et al67 there was no association with graft function at any 
time interval. Hence our results also supported the dose response relationship of hyperuricemia 
with graft function proposed by Min et al. 
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Conclusion: 
 Prevalence of hyperuricemia was 26.8%.  
 Hyperuricemia was predominantly early onset 89%. 
 Early onset moderate to severe hyperuricemia as defined in our study was seen in 29.5% 
patients. 
 Among the baseline characteristics only body mass index was associated with 
hyperuricemia which was higher in this group. 
 Predominant maintenance immunosuppression was tacrolimus and mycophenolate based 
regimen in our study. 
 The nadir eGFR and eGFR at 1month  was lower in hyperuricemic patients 
 Among the patients who had an early onset moderate to severe hyperuricemia the eGFR at 
1 year was lower. 
 There was no association of early onset mild hyperuricemia with eGFR at any time post- 
transplant. 
 The incidences of NODAT and serum level of triglycerides were higher in hyperuricemic 
recipients. 
 There was no association between deceased donor, recipient gender, type of induction 
regimen and delayed graft function. 
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Table  12. Summary of studies on hyperuricemia in renal allograft recipients 
 
 
Study Study design No. of 
patients 
Immunosupression Prevalence of 
hyperuricemi
a 
Graft 
outcome 
Association 
Gores et al
62 
 
Prospective 131 CsA 80% No diff. -------- 
Akgul et al63 Retrospective 133 CsA 84.6% No diff. -------- 
Meier-
Kriesche et 
al10 
Prospective 
( Symphony 
trial) 
1645 Csa/Tac/mTor inh. 19-55% No diff Obese, CsA use, 
deceased donor, poor 
baseline graft 
function 
Akalin et al84 Retrospective 307 ---------- 47% No diff Male sex, deceased 
donor,higher CAN, 
graft loss, poor 
baseline graft 
function 
Gerhardt et 
al64 
Retrospective 350 CsA/Tac -------------- Adverse  -------- 
Armstrong et 
al.65 
Retrospective 90 CsA/Tac 80% Adverse Hypertension, eGFR 
at 2years 
Bandukwala 
et al68 
Retrospective 405 Tac/CsA 44% Adverse diuretic use, duration 
of followup, and 
triglycerides 
Our study Retrospective 284 Tac 27% Adverse High BMI at 
transplant, low nadir 
GFR and GFR at1mth, 
dyslipidemia, 
elevated triglyceride 
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Proforma 
DEPARTMENT OF NEPHROLOGY 
CHRISITIAN MEDICAL COLLEGE AND HOSPITAL 
VELLORE 
 
Case Number:   
1) Recipient Name:  
2) Recipient HT : 
3) Recipient WT: 
4) R. Hosp. No: 
5) R. Age: 
6) R. Sex:   Female -1 / Male -0 
7) Dialysis: No - 0  /    HD-1   /   CAPD-2     
8) Duration of Dialysis:  
9) Pre Tx DM :  No – 0   /   Yes – 1 
10) Pre Tx HTN:  No – 0   /   Yes – 1 
11) Live related -0 / Cadaver -1  
12) Donor Age: 
13) Donor Sex:   Female -0 / Male -1 
14) HLA Match: 
15) Induction: Nil  – 0 / Simulect – 1 / ATG – 2   
16) Nadir Creat: 
17) Post Tx day of nadir creat( the lowest creatinine just before an increase noted-Day O) 
 52 
18) Subsquent eGFR of Recipient 
M
mth 
e
GFR 
W
weight  
M
mth 
e
GFR 
W
weight 
1
1 
  1
5 
  
2
2 
  1
6 
  
3
3 
  2
12 
  
4
4 
  3
18 
  
2
24 
  4
48 
  
4
36 
  6   
 
 
19) DGF Yes-0, No-1 
20) Prednisolone: No -0  /  Yes -1 
21) Cyclosporin: No -0  /  Yes -1 
22) Tacrolimus: No -0  /  Yes -1 
23) Azathioprine:  No -0  /  Yes -1 
24) MMF:  No -0    /    Yes – 1    
25) Presence of acute rejection 
26) No. of Rejection episodes: 
27) Post  HTN (number of drugs used for BP control) : No -0  /  Yes (num): 
28) New Onset diabetes after transplant  DM: No -0  /  Yes -1 
29) Hyperuricemia : Yes-1/No-0 
30) Hyperuricemia after transplant duration – (mth) 
31) Early /Late hyperuricemia(</>1yr) : Yes-1/Late -0 
32) Graft loss – Yes -1/No-0 
       Death – Yes-1/No-0  
33) Graft function of last visit 
 53 
34) Native kidney disease  
1- DN 
2-  unknown 
3- FSGS 
4- CGN 
5- ADPKD 
6- Obstructive uropathy 
35) Dyslipidemia at time of diagnosis of hyperuricemia – Yes-1/No-0 
LDL- /TG-/HDL-/ Totalcholesterol 
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